Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 18/20 | 0.57 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2902224 | 1.00 | PPARG (0.57) | PPARGPTGDR2AKR1B1 | |
| SCHEMBL2902497 | 0.93 | PPARG (0.66) | PPARGPTGDR2AKR1B1 | |
| SCHEMBL2903640 | 0.92 | PPARG (0.57) | PPARGPTGDR2AKR1B1 | |
| SCHEMBL2902698 | 0.91 | PPARG (0.60) | PPARGPTGDR2 | |
| SCHEMBL2904117 | 0.88 | PPARG (0.63) | PPARGPTGDR2 | |
| SCHEMBL2904111 | 0.88 | PPARG (0.63) | PPARGPTGDR2 | |
| SCHEMBL2900823 | 0.86 | PPARG (0.63) | PPARGPTGDR2 | |
| SCHEMBL2896224 | 0.86 | PPARG (0.63) | PPARGPTGDR2 | |
| SCHEMBL2898058 | 0.83 | PPARG (0.74) | PPARG | |
| SCHEMBL2901679 | 0.83 | PPARG (0.74) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537078-B1 | INDOLES HAVING ANTI-DIABETIC ACTIVITY | MERCK SHARP & DOHME (US) | 2010-04-14 | — | — | EP | claimed |
| US-7186746-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | claimed |
| US-20050277685-A1 | Indoles having anti-diabetic activity | MERCK SHARP & DOHME LLC | 2005-12-15 | — | — | US | claimed |
| US-7345085-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345085-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345085-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070161689-A1 | Indoles having anti-diabetic activity | MERCK SHARP & DOHME LLC | 2007-07-12 | — | — | US | disclosed |
| US-20070161689-A1 | Indoles having anti-diabetic activity | MERCK SHARP & DOHME LLC | 2007-07-12 | — | — | US | disclosed |
| US-20070161689-A1 | Indoles having anti-diabetic activity | MERCK SHARP & DOHME LLC | 2007-07-12 | — | — | US | disclosed |
| US-7186746-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186746-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186746-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050277685-A1 | Indoles having anti-diabetic activity | MERCK SHARP & DOHME LLC | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277685-A1 | Indoles having anti-diabetic activity | GPR119, PPARA, PPARG | PPARG 3/4885PTGDR2 185/4885AKR1B1 1018/4885 |
| US-20070161689-A1 | Indoles having anti-diabetic activity | GPR119, PPARA, PPARG | PPARG 3/4885PTGDR2 185/4885AKR1B1 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.